cancer – Page 8 – media

Illumina and KingMed to develop oncology diagnostics in China

US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.
- Source: Verdict Medical Devices
- 640
- January 9, 2018
cancer CFDA Company Insight digital health
J&J signs 15 deals for new healthcare solutions

Johnson & Johnson (J&J) has signed 15 new partnerships to explore, develop and advance new medical devices, therapeutics and consumer health solutions.
- Source: Verdict Medical Devices
- 706
- January 9, 2018
AI cancer Company Insight Johnson & Johnson
Silencing ‘junk’ gene could halt tumor growth

The gene is in an area of the genome that does not contain instructions for making proteins. At one time, it was thought that this non-coding area was just irrelevant "junk."
- Source: Medicalnewstoday
- 534
- December 20, 2017
cancer Researches tumor
Atlas and OrbiMed back Boston’s Kyn in $49M round to pursue immunometabolism therapies

Kyn is led by an Atlas entrepreneur-in-residence Mark Manfredi, who was previously chief scientific officer at Raze Therapeutics (also an Atlas-funded startup). Raze raised a $24 million Series A in 2014, but the company appears to have wound down pretty quickly. The website is no longer active, and Manfredi said Raze still has some assets and collaborations, but no longer employs anyone. Atlas’ Bruce Booth says the underlying cancer metabolism biology was too complicated to warrant further investment. Before Raze, Manfredi was VP of oncology biology at Takeda.
- Source: Endpts
- 508
- December 18, 2017
cancer immunometabolism Market Views Series
Chi-Med Initiates Fruquintinib U.S. Clinical Trials

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) 1, 2 and 3, that has met its primary endpoint in several Phase II and III clinical trials in China for the treatment of colorectal, lung and gastric cancers. The clinical study in the U.S. is a multi-center, open-label, Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of fruquintinib in U.S. patients with advanced solid tumors. The first drug dose was administered earlier this month. Additional details about this study may be found at clinicaltrials.gov, using identifier NCT03251378.
- Source: chi-med
- 669
- December 18, 2017
cancer Clinical Trials Fruquintinib
Men with HPV are 20 times more likely to be reinfected after one year

The study, published December 5 in the Proceedings of the National Academy of Sciences, highlights the importance of vaccination for preventing the spread of HPV in young men before they become sexually active. Vaccination could potentially prevent reinfection in older men who have already contracted the virus.
- Source: medicalxpress
- 643
- December 6, 2017
cancer HPV Researches vaccination
Researchers show aspirin added to cancer drug improves effectiveness

Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.
- Source: medicalxpress
- 593
- December 5, 2017
aspirin cancer colorectal lung pancreatic Researches
Mouth bacteria linked to esophageal cancer

An analysis of microbes sampled from the mouths of more than 120,000 people has found that two types of bacteria that lead to gum disease are also linked to higher risk of esophageal cancer.
- Source: medicalnewstoday
- 617
- December 4, 2017
cancer mouth bacteria Researches
Gottlieb Says Faster Cancer Drug Approvals Coming for Secondary Indications

US Food and Drug Administration (FDA) Commissioner Scott Gottlieb and NIH Director Francis Collins testified on Thursday before the House Energy & Commerce Committee on how their agencies have worked to implement provisions from the 21st Century Cures Act passed and signed by President Barack Obama a month before he left office.
- Source: raps.org
- 686
- December 4, 2017
cancer FDA NIH Policy
When PSA Is 4-10, phi Test Helps With Biopsy Decision

The Prostate Health Index (phi) (Beckman Coulter) significantly changes urologists' opinions about whether men with certain results on prostate-specific antigen (PSA) screening should or should not undergo a prostate biopsy to assess for cancer, according to new observational research.
- Source: medscape
- 823
- December 1, 2017
cancer PSA Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.